Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (15203)	1/11/2005 2:37:24 PM
From: Ian@SI	Respond to of 52153

... the Xyotax patients went five or six rounds while the taxol patients went only two or three (or maybe it was one or two - I forget) is still striking though. Perhaps, if MJ's thesis is correct, our kidneys are very efficient at clearing the drug from our systems. Thus 5 or 6 Xyotax rounds with 90% pissed away is still less than 1 Taxol treatment! The apparent survival advantage as the PhIII continues still seems quite positive to me. Last time I listened to CTIC webcast, the "events milestone" was supposed to be attained this week with another 8 weeks to lock and analyse the database. Ian

To: Biomaven who wrote (15203)	1/11/2005 4:48:35 PM
From: kenhott	Read Replies (3) \| Respond to of 52153

My main point, if I even have one, is CTIC is no slam dunk or a layup like some people are thinking. Be very careful, the shorts are not being stupid. In Stellar 3, the largest site info is interesting. But I asked myself this. Why no more data of this type? The largest site had 23 patients. 6 cycles vs. 2-3 cycles. 23 is only 6% of total. How hard is it to go to the top 10 sites or top 20 sites or top 30 sites etc. and ask the same or more questions? Maybe you can get to 30 or 40% or more of the enrollment that way. Why didn't they do that? If they did, why didn't they give out the data? Why stop at one site either way?